CLINICAL_TRIALS
withdrawal
· 2012-07-31
Clinical Trial Update: Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma [Phase 2]
Summary
A Phase 2 study of sunitinib in patients with high-risk renal cell carcinoma has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Renal Cell Carcinoma | Phase 2 | Status: WITHDRAWN